- Home
- WXM vs CLRB Comparison
WXM vs CLRB Comparison
Compare WXM & CLRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WXM
- CLRB
- Stock Information
- Founded
- WXM 2009
- CLRB 2002
- Country
- WXM China
- CLRB United States
- Employees
- WXM N/A
- CLRB N/A
- Industry
- WXM
- CLRB Biotechnology: Pharmaceutical Preparations
- Sector
- WXM
- CLRB Health Care
- Exchange
- WXM NYSE
- CLRB Nasdaq
- Market Cap
- WXM 15.3M
- CLRB 12.5M
- IPO Year
- WXM 2025
- CLRB N/A
- Fundamental
- Price
- WXM $2.20
- CLRB $0.28
- Analyst Decision
- WXM
- CLRB Hold
- Analyst Count
- WXM 0
- CLRB 2
- Target Price
- WXM N/A
- CLRB N/A
- AVG Volume (30 Days)
- WXM 100.6K
- CLRB 690.5K
- Earning Date
- WXM 01-01-0001
- CLRB 05-13-2025
- Dividend Yield
- WXM N/A
- CLRB N/A
- EPS Growth
- WXM 67.61
- CLRB N/A
- EPS
- WXM 0.18
- CLRB N/A
- Revenue
- WXM $15,524,259.00
- CLRB N/A
- Revenue This Year
- WXM N/A
- CLRB N/A
- Revenue Next Year
- WXM N/A
- CLRB N/A
- P/E Ratio
- WXM $14.47
- CLRB N/A
- Revenue Growth
- WXM 10.86
- CLRB N/A
- 52 Week Low
- WXM $1.52
- CLRB $0.22
- 52 Week High
- WXM $7.99
- CLRB $3.42
- Technical
- Relative Strength Index (RSI)
- WXM N/A
- CLRB 57.83
- Support Level
- WXM N/A
- CLRB $0.23
- Resistance Level
- WXM N/A
- CLRB $0.26
- Average True Range (ATR)
- WXM 0.00
- CLRB 0.02
- MACD
- WXM 0.00
- CLRB 0.00
- Stochastic Oscillator
- WXM 0.00
- CLRB 76.65
About WXM WF INTERNATIONAL LIMITED
WF International Ltd is engaged in the provision of supply, installation, fitting-out and maintenance services for HVAC system and floor heating systems. It provides the supply, installation and fitting-out services for HVAC systems for large-scaled commercial projects consisting of offices, hotels, manufactures, airports and hospitals, such as the International Finance Square HVAC projects across China, Chengdu Vanke Charm City, Chengdu Raffles Plaza, Chengdu Yinshi Plaza, Chengdu Metro No. Ten Line, and Panzhihua Jinhai Hotel.
About CLRB Cellectar Biosciences Inc.
Cellectar Biosciences Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of drugs for the treatment of cancer. The company's core objective is to leverage a proprietary phospholipid drug conjugate (PDC) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and safety as a result of fewer off-target effects. It has one operating and reportable segment focused on utilizing its PDC platform to develop drugs for the treatment of cancer.